A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren
Latest Information Update: 22 Mar 2019
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Pharmacodynamics; Registrational
- Sponsors Novartis
- 27 Mar 2018 Status changed from active, no longer recruiting to completed.
- 04 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 04 Oct 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.